Caremax Hospice 1100 E Broadway, Suite 304, Glendale, CA, 91205 | |
(818) 242-7606 |
News Archive
CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today announced the completion of a $22.1M financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
An incentive-based program that now reaches 4.5 million families in Mexico is associated with lowering the rate of anemia and improving growth in low-income, rural infants and children, according to a study in the June 2 issue of the Journal of the American Medical Association (JAMA), a theme issue on Global Health.
› Verified 6 days ago
Name | Caremax Hospice |
---|---|
Location | 1100 E Broadway, Suite 304, Glendale, California |
Hospice ID | 551796 |
Category | Freestanding Hospice |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
Accreditation Provider | The Joint Commission (TJC) |
SSA county code | 200 |
News Archive
CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today announced the completion of a $22.1M financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
An incentive-based program that now reaches 4.5 million families in Mexico is associated with lowering the rate of anemia and improving growth in low-income, rural infants and children, according to a study in the June 2 issue of the Journal of the American Medical Association (JAMA), a theme issue on Global Health.
› Verified 6 days ago
NPI Number | 1720413339 |
Organization Name | Hidden Hills Hospice And Palliative Care, Llc |
Address | 1100 E Broadway Ste 304 Glendale, California, 91205 |
Phone Number | (818)242-7606 |
News Archive
CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today announced the completion of a $22.1M financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
An incentive-based program that now reaches 4.5 million families in Mexico is associated with lowering the rate of anemia and improving growth in low-income, rural infants and children, according to a study in the June 2 issue of the Journal of the American Medical Association (JAMA), a theme issue on Global Health.
› Verified 6 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | Not Available | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | Not Available | 93.6 |
Patients who were checked for pain at the beginning of hospice care | Not Available | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | Not Available | 97.3 |
Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today announced the completion of a $22.1M financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
An incentive-based program that now reaches 4.5 million families in Mexico is associated with lowering the rate of anemia and improving growth in low-income, rural infants and children, according to a study in the June 2 issue of the Journal of the American Medical Association (JAMA), a theme issue on Global Health.
› Verified 6 days ago
Home Health Aides | 1 |
Counselors | 1 |
Licensed Practical or Vocational Nurses | 1 |
Medical Social Workers | 1 |
Physicians | 1 |
Registered Nurses | 4 |
Other Personnel | 1 |
Total Employees | 10 |
---|
News Archive
CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today announced the completion of a $22.1M financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
An incentive-based program that now reaches 4.5 million families in Mexico is associated with lowering the rate of anemia and improving growth in low-income, rural infants and children, according to a study in the June 2 issue of the Journal of the American Medical Association (JAMA), a theme issue on Global Health.
› Verified 6 days ago
Others | 1 |
Total Volunteers | 1 |
---|
News Archive
CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today announced the completion of a $22.1M financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial.
In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
An incentive-based program that now reaches 4.5 million families in Mexico is associated with lowering the rate of anemia and improving growth in low-income, rural infants and children, according to a study in the June 2 issue of the Journal of the American Medical Association (JAMA), a theme issue on Global Health.
› Verified 6 days ago
All Care Hospice Location: 100 W Broadway Avenue, Suite 810, Glendale, California, 91210 Phone: (818) 242-7606 |
Seasons Hospice & Palliative Care Of California Location: 320 W Arden Ave, Suite 100, Glendale, California, 91203 Phone: (818) 242-7606 |
St Anthony Hospice Location: 512 E Wilson Ave Suite 208, Glendale, California, 91206 Phone: (818) 242-7606 |
Pleasant Day Hospice, Inc. Location: 434 W. Colorado St. Suite 201, Glendale, California, 91204 Phone: (818) 242-7606 |